[go: up one dir, main page]

DE69816060D1 - Verwendung von 5ht3 antagonisten zum fördern der darmspülung - Google Patents

Verwendung von 5ht3 antagonisten zum fördern der darmspülung

Info

Publication number
DE69816060D1
DE69816060D1 DE69816060T DE69816060T DE69816060D1 DE 69816060 D1 DE69816060 D1 DE 69816060D1 DE 69816060 T DE69816060 T DE 69816060T DE 69816060 T DE69816060 T DE 69816060T DE 69816060 D1 DE69816060 D1 DE 69816060D1
Authority
DE
Germany
Prior art keywords
antagonists
colon
promote
concerned
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69816060T
Other languages
English (en)
Other versions
DE69816060T2 (de
Inventor
Adrianus Megens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of DE69816060D1 publication Critical patent/DE69816060D1/de
Publication of DE69816060T2 publication Critical patent/DE69816060T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/765Polymers containing oxygen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
DE69816060T 1997-04-18 1998-04-14 Verwendung von 5ht3 antagonisten zum fördern der darmspülung Expired - Lifetime DE69816060T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97201149 1997-04-18
EP97201149 1997-04-18
PCT/EP1998/002356 WO1998047481A1 (en) 1997-04-18 1998-04-14 Use of 5ht3 antagonists for promoting intestinal lavage

Publications (2)

Publication Number Publication Date
DE69816060D1 true DE69816060D1 (de) 2003-08-07
DE69816060T2 DE69816060T2 (de) 2004-04-22

Family

ID=8228223

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69816060T Expired - Lifetime DE69816060T2 (de) 1997-04-18 1998-04-14 Verwendung von 5ht3 antagonisten zum fördern der darmspülung

Country Status (12)

Country Link
US (2) US6235745B1 (de)
EP (1) EP0975327B1 (de)
JP (1) JP2001523239A (de)
KR (1) KR100529512B1 (de)
AT (1) ATE243993T1 (de)
AU (1) AU745361B2 (de)
CA (1) CA2286076C (de)
DE (1) DE69816060T2 (de)
DK (1) DK0975327T3 (de)
ES (1) ES2202855T3 (de)
PT (1) PT975327E (de)
WO (1) WO1998047481A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1090638A1 (de) * 1999-10-08 2001-04-11 Sanofi-Synthelabo Verwendung von (R)-Zacopride oder dessen Salz zur Herstellung eines Medikaments für die Behandlung von Schlafapnoe
EP1347779A2 (de) * 2000-11-24 2003-10-01 Janssen Pharmaceutica N.V. Verwendung einer dreifach-kombination mit einem 5ht3-antagonisten, einem 5ht4-agonisten und einem laxativum zur förderung der darmspülung
PE20021019A1 (es) 2001-04-19 2002-11-13 Upjohn Co Grupos azabiciclicos sustituidos
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
TWI332943B (en) * 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
US6946149B2 (en) * 2002-04-30 2005-09-20 Braintree Laboratories, Inc. Salt solution for colon cleansing
WO2004031184A1 (en) * 2002-10-01 2004-04-15 Johnson & Johnson Pharmaceutical Research & Development, Inc. 4,6-diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors
US6996500B2 (en) * 2002-10-30 2006-02-07 Hewlett-Packard Development Company, L.P. Method for communicating diagnostic data
BRPI0406748A (pt) * 2003-01-13 2005-12-20 Dynogen Pharmaceuticals Inc Método de tratamento de náusea, vÈmito e ânsia de vÈmito ou qualquer combinação destes em um paciente que necessite do mesmo e composição farmacêutica
US20040147509A1 (en) * 2003-01-13 2004-07-29 Dynogen Pharmaceuticals, Inc. Method of treating functional bowel disorders
DE602004007225T2 (de) * 2003-04-04 2008-03-06 Dynogen Pharmaceuticals Inc., Waltham Methode zur behandlung von erkrankungen der unteren harnwege
US7049319B2 (en) 2003-09-23 2006-05-23 Semaan Abboud Colon cleansing composition and method
WO2005099698A1 (ja) * 2004-04-15 2005-10-27 Eisai R & D Management Co., Ltd. 安定化された4-アミノ-5-クロロ-N-[(1R,3r,5S)-8-メチル-8-アザビシクロ[3.2.1]オクタ-3-イル]-2-[1-メチルブタ-2-インイルオキシ]ベンズアミド含有組成物
US20060293309A1 (en) * 2005-03-28 2006-12-28 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
WO2007019888A2 (en) * 2005-08-12 2007-02-22 Ctg Pharma S.R.L. Therapeutic compositions containing mesalamine and a co-agent for treating colon diseases
AU2006279891B2 (en) * 2005-08-16 2010-03-11 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amide) formulation
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP2061460A2 (de) * 2006-08-07 2009-05-27 Albany Molecular Research, Inc. 2-aminobenzoxazol-carboxamide als 5ht3-modulatoren
US7553846B2 (en) 2006-08-07 2009-06-30 Albany Molecular Research, Inc. 2-alkylbenzoxazole carboxamides as 5-HT3 modulators
CA2902348C (en) * 2013-02-25 2021-11-30 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
RS59667B1 (sr) 2013-03-15 2020-01-31 Braintree Laboratories Inc Oralna farmaceutska kompozicija sulfatnih soli u obliku tableta dvostruke primene i postupci njihove upotrebe
US10172833B2 (en) 2015-08-11 2019-01-08 Insys Development Company, Inc. Sublingual ondansetron spray
US10143656B1 (en) 2017-08-04 2018-12-04 Braintree Laboratories, Inc. Solid oral sulfate salt formulations for cleaning a colon and methods of using same
US11970483B2 (en) 2018-09-28 2024-04-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
US12239659B2 (en) 2023-06-15 2025-03-04 Braintree Laboratories, Inc. Methods of administering safe colon cleansing compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB893267A (en) 1958-11-25 1962-04-04 Sterling Drug Inc Laxative enemas
US5166145A (en) * 1990-09-10 1992-11-24 Alza Corporation Antiemetic therapy
TW294595B (de) 1992-11-20 1997-01-01 Janssen Pharmaceutica Nv
WO1996014071A1 (es) 1994-11-04 1996-05-17 Legarda Ibanez Juan Jose Combinacion de farmacos como medicamento destinado a supresion de dependencia de individuos a opiaceos
US6103734A (en) 1994-11-04 2000-08-15 Legarda Ibanez; Juan Jose Drug combination as a medicament to suppress the dependence of individuals to opiates
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis

Also Published As

Publication number Publication date
ES2202855T3 (es) 2004-04-01
US6235745B1 (en) 2001-05-22
CA2286076A1 (en) 1998-10-29
DE69816060T2 (de) 2004-04-22
WO1998047481A1 (en) 1998-10-29
EP0975327B1 (de) 2003-07-02
AU7528298A (en) 1998-11-13
US20010020025A1 (en) 2001-09-06
CA2286076C (en) 2006-12-12
JP2001523239A (ja) 2001-11-20
AU745361B2 (en) 2002-03-21
US6555546B2 (en) 2003-04-29
KR20000075858A (ko) 2000-12-26
ATE243993T1 (de) 2003-07-15
PT975327E (pt) 2003-11-28
DK0975327T3 (da) 2003-10-20
KR100529512B1 (ko) 2005-11-22
EP0975327A1 (de) 2000-02-02

Similar Documents

Publication Publication Date Title
DE69816060D1 (de) Verwendung von 5ht3 antagonisten zum fördern der darmspülung
TR200000782T2 (tr) Resorsinol türevleri.
DE69819311D1 (de) Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase
TR200000073T2 (tr) 5-HT6 Reseptör antagonistleri olan sülfonamid türevleri ve bunların hazırlanma prosesi
BR9911621A (pt) Bifenil sulfonamidas como antagonista duplos de receptor de angiotensina endotelina
EA199900693A1 (ru) Атропизомеры 3-арил-4(3h)-хиназолинонов и их использование в качестве антагонистов амра-рецепторов
EA200300595A1 (ru) Соединения пиперазинилпиразинов в качестве антагонистов серотонин 5-ht2 рецептора
NO964236D0 (no) Anvendelse av serotonin-antagonister (5HT3) for behandling av fibromyalgi
TR970073A2 (tr) Alfa adrenerjik resentör antagonistleri olarak pirimidindion pirimidintrion,triazindion, tetrahidrokinazolindion türevleri.
CU22997A3 (es) Proteína híbrida para la inhibición de la desgranulación de los mastocitos y su utilización
ATE274348T1 (de) Überbrückte indenopyrrolocarbazole
SE9702773D0 (sv) Novel compounds
TR200200460T2 (tr) Yeni fenilpiperazinler
TR200002896T2 (tr) Kalsilitik Bileşimler
DE69804198D1 (de) Zementschlamm für die zementierung von bohrlöchern insbesondere ölbohrlöchern
EA200000536A1 (ru) Применение комбинации ингибитора конвертирующего фермента и диуретика для лечения нарушений микроциркуляции
DE69934305D1 (de) Verwendung von dexmedetomidine zur sedierung auf der intensivstation
EA200100517A1 (ru) Антагонисты 5ht1 для антидепрессантной терапии
TR200102742T2 (tr) Rezorsinol türevleri
DE69915486D1 (de) Verwendung von eletriptan zur vorbeugung des wiederauftretens der migräne
EA200200727A1 (ru) Новые производные индола
TR200001080T2 (tr) 2 ile ikame edilmiş 1,2-Benisotiyazol türevleri ve bunların serrotonın antagonistleri
TR200003203T2 (tr) Karboksaldehitin saflaştırılması
DE59803066D1 (de) Substituierte benzyloxyimino-verbindungen
PE20399A1 (es) Muteina ob

Legal Events

Date Code Title Description
8364 No opposition during term of opposition